SBC Medical Group (NASDAQ:SBC) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded SBC Medical Group from “buy” to “strong-buy,” while the broader analyst consensus remains “Moderate Buy” with an average price target of $8.50.
• SBC shares opened at $5.09, near their 12-month high of $5.29, and have risen above their 50-day and 200-day moving averages. The company reported quarterly revenue of $49.19 million, exceeding estimates, but earnings per share of $0.10 fell short of expectations.
• Institutional ownership stands at 60.82%, with BlackRock, Citadel Advisors and other investors recently acquiring positions in the company.

SBC Medical Group (NASDAQ:SBC - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued to clients and investors on Monday, Wall Street Zen reports.

SBC has been the topic of a number of other research reports. Weiss Ratings raised shares of SBC Medical Group from a "sell (d+)" rating to a "hold (c-)" rating in a report on Tuesday, September 22nd. BTIG Research reaffirmed a "buy" rating and set a $8.00 price target on shares of SBC Medical Group in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $8.50.

SBC Medical Group Price Performance

Shares of SBC Medical Group stock opened at $5.09 on Monday. The company has a current ratio of 3.31, a quick ratio of 3.27 and a debt-to-equity ratio of 0.09. SBC Medical Group has a twelve month low of $2.78 and a twelve month high of $5.29. The stock has a market cap of $523.51 million, a price-to-earnings ratio of 10.83, a price-to-earnings-growth ratio of 2.29 and a beta of 0.56. The company has a fifty day moving average price of $4.04 and a 200 day moving average price of $3.62.

SBC Medical Group (NASDAQ:SBC - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported $0.10 EPS for the quarter, missing analysts' consensus estimates of $0.12 by ($0.02). The firm had revenue of $49.19 million during the quarter, compared to analyst estimates of $45.37 million. SBC Medical Group had a return on equity of 18.47% and a net margin of 27.99%. Equities research analysts forecast that SBC Medical Group will post 0.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SBC Medical Group

Several large investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of SBC Medical Group during the second quarter valued at approximately $2,846,000. Citadel Advisors LLC acquired a new stake in SBC Medical Group in the second quarter worth approximately $446,000. Segall Bryant & Hamill LLC bought a new position in SBC Medical Group during the 1st quarter valued at $340,000. Bank of New York Mellon Corp bought a new position in SBC Medical Group during the 2nd quarter valued at $83,000. Finally, Central Pacific Bank Trust Division acquired a new position in shares of SBC Medical Group during the 2nd quarter valued at $74,000. Institutional investors and hedge funds own 60.82% of the company's stock.

SBC Medical Group Company Profile

SBC Medical Group Holdings Incorporated NASDAQ: SBC is a healthcare company focused on supporting medical institutions, particularly clinics that provide aesthetic and cosmetic medical treatments. Its business includes management services, operational support and products designed to help medical providers deliver care and manage their practices.

The company is associated with the Shonan Beauty Clinic network, which offers services such as cosmetic surgery, dermatology, hair restoration and other aesthetic procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.